Chinese medicine injections fear loss of heat pin-off anti-thrombosis pattern rearm

reduce the amount of Chinese medicine injections and auxiliary drugsPoint of view: Remove the front-row halo of hospital sales
In 2016, the market size of 95 hospitals with common Chinese medicine injections was about 16.2 billion yuan. Since 2016, chinese medicine injections in the list of key drugs in each province have accounted for more than 90% of all Chinese medicine injections, and the top ten products in the total amount of Chinese medicine injection hospitals have entered the key drug monitoring catalogue.
Further limitations on the clinical use of Chinese medicine injections in 2017: With the release of the Health Insurance Directory in February 2017, the medical insurance restrictions for Chinese medicine injections were strict, with restricted products being heat-detoxifying, cardiovascular, and anti-tumor classes.
And anti-thrombotic injections in the medical insurance restrictions before the release of most of the hospital market sales of the top products, blood-sucking injections, Shu hemoinin injections, brain-wake injections, Danhong injections and injections of dansan polyphenols are in the top 10 chinese medicine injection hospital size of the total amount of the list. As shown in table 1, the increased health-care restrictions are primarily channel-based and are expected to affect the size of sales.
western medicine, injections such as neuroresuperatives, repair, nutrition, cerebrovascular dilation agents, which complement the status of drugs in antithrombosis therapy, are also restricted, as shown in Table 2, with different limits on the age of adaptation and use. With the further development of clinical pathway, the clinical use of such drugs is more and more limited.Incremental Direct Coagulase Inhibitors and Direct Xa Factor InhibitorsPoint of View: New health insurance products deserve attention
However, the limited medical insurance for Chinese medicine injections and complementary medications is expected to bring some room for growth in anti-thrombosis treatment drugs.
The 2017 edition of the Health Insurance Catalog divides antithrombosis drugs into vitamin K antagonists, heparin, plate small plate coagulation inhibitors, except for heparin, enzymes, direct clotting enzyme inhibitors, direct Xa factor inhibitors, and other antithrombosis drugs in Category 7. The new health insurance products are Etiba peptide, pyridine, agaculban, dabiga esters, apixaban, sulfonda liver sodium and shulodit.
heparin sample hospital market size is more than 50 million yuan. Plateplate coagulation inhibitors (except heparin) stand out with clopidogrete. Direct Xa Factor inhibitors only Devasaban entered health insurance in 2009, and there is expected to be a significant increase in apixaban, sulfonda liver sodium and schulodet health insurance in 2017. For the first time, direct clotting enzyme inhibitors have products entered the health insurance catalog.imitation clopidogrel, devasaban, apixaban and tigrilloPoint of view: four products imitation heat is high
after 2016, anti-thrombosis drugs entered Clinical new drugs are few, domestic enterprises only Chinese the PLA Academy of Military Medical Sciences Institute of Radiological and Radiological Medicine and Beijing Sanyo and Ze Biotech Co., Ltd. jointly developed the injection recombinant new cylindrical initiation phase I. clinical trials, its adaptation is deep vein thrombosis in the lower extremities. Novart's recombined otter product, desirudin, is listed abroad but is not available at home.
-generics, although the chemical generics consistent evaluation of the project quality requirements are getting higher and higher, project costs are also greatly improved with the improvement of standards, but manufacturers against thrombosis drugs generic drug declaration is still hot, mainly concentrated in hydrochlorochloride tablets, devasaban tablets, apixaban tablets and tigrillo tablets 4 products. AstraZeneta's Tigrillo tablets, which did not make the 2017 health-care list released in February, entered the list of health-care catalog negotiations at 8.45 yuan (90 mg/piece) and were included in the national list of essential health insurance, work-related injury insurance and maternity insurance drugs.of <<<
chinese medicine injections and ancillary drugs are expected to decline in sales after health insurance restrictions, thus creating room for the growth of therapeutic drugs. Judging from the current status quo of the declaration of four anti-thrombosis drugs, the production enterprises that used to rely on a single Chinese medicine injection and auxiliary drug to support their performance have not yet begun to compete for the popular generic drugs. (Medical Economics)